Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Cash Generation Expanding
Trending higher, above historical average, slight contraction.
Left:
|
|
|
|

Operating cash flow minus capital expenditures

Latest
$-23.66M
↑ 18% above average
Average (9y)
$-28.91M
Historical baseline
Range
High:$646000.00
Low:$-49.88M
CAGR
-8.0%
Structural decline
PeriodValueChange
2024$-23.66M+19.1%
2023$-29.24M-4626.3%
2022$646000.00+102.7%
2021$-23.91M-20.7%
2020$-19.82M+38.8%
2019$-32.39M+5.2%
2018$-34.17M-7.3%
2017$-31.84M+29.0%
2016$-44.85M+10.1%
2015$-49.88M-